William Burman is an Infectious Disease physician affiliated with Denver Health Medical Center. OpenAlex indexes 163 publications with 9,735 citations (h-index 54); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
777 Bannock St
Mc 7782
Denver, CO 802044507
Telephone
303-602-8723Provider last certified this registry record 10 May 2024.
Clinical trials
- TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment
Sponsor: Centers for Disease Control and Prevention
- TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
Sponsor: Centers for Disease Control and Prevention
- TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
Sponsor: Centers for Disease Control and Prevention
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- QIAGEN, LLCProgram year20251 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2011–2013 per NIH RePORTER. The latest:
- CATEGORY B: IMPLEMENTATION/CRAFT: CARDIOVASCULAR DISEASE REDUCTION: A FOCUSED TRA
Denver Health and Hospital Authority
FY2013$610,345U58DP003493 - CATEGORY B: IMPLEMENTATION/CRAFT: CARDIOVASCULAR DISEASE REDUCTION: A FOCUSED TRA
Denver Health and Hospital Authority
FY2012$610,345U58DP003493 - CATEGORY B: IMPLEMENTATION/CRAFT: CARDIOVASCULAR DISEASE REDUCTION: A FOCUSED TRA
Denver Health and Hospital Authority
FY2011$610,345U58DP003493
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach
Infection Control and Hospital Epidemiology
2017 - Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to <i>Mycobacterium tuberculosis</i>
Proceedings of the National Academy of Sciences
2013 - Avoidable Antibiotic Exposure for Uncomplicated Skin and Soft Tissue Infections in the Ambulatory Care Setting
The American Journal of Medicine
2013 - Decreased Antibiotic Utilization After Implementation of a Guideline for Inpatient Cellulitis and Cutaneous Abscess
Archives of Internal Medicine
2011
Similar KOLs
Other experts from the same institution or the same specialty.
Pamela Peterson, MD
Denver Health Medical Center
Connie Price, MD, MBA
Denver Health Medical Center
Daniel Bessesen, MD
Denver Health Medical Center
Lawrence Karsh, MD
Denver Health Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”